Werewolf Therapeutics (NASDAQ:HOWL) vs. Kymera Therapeutics (NASDAQ:KYMR) Head-To-Head Survey

Kymera Therapeutics (NASDAQ:KYMR) and Werewolf Therapeutics (NASDAQ:HOWL) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, dividends, profitability, valuation, institutional ownership, earnings and analyst recommendations.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Kymera Therapeutics and Werewolf Therapeutics, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kymera Therapeutics	1	0	21	1	2.96
Werewolf Therapeutics	1	4	2	0	2.14

Kymera Therapeutics currently has a consensus price target of $117.14, suggesting a potential upside of 30.30%. Werewolf Therapeutics has a consensus price target of $3.75, suggesting a potential upside of 990.12%. Given Werewolf Therapeutics’ higher possible upside, analysts plainly believe Werewolf Therapeutics is more favorable than Kymera Therapeutics.

Profitability

This table compares Kymera Therapeutics and Werewolf Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Kymera Therapeutics	-611.94%	-24.71%	-22.05%
Werewolf Therapeutics	N/A	-208.23%	-75.12%

Insider & Institutional Ownership

64.8% of Werewolf Therapeutics shares are owned by institutional investors. 16.0% of Kymera Therapeutics shares are owned by company insiders. Comparatively, 23.6% of Werewolf Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Earnings and Valuation

This table compares Kymera Therapeutics and Werewolf Therapeutics”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kymera Therapeutics	$39.21 million	188.60	-$311.35 million	($3.57)	-25.18
Werewolf Therapeutics	N/A	N/A	-$60.82 million	($1.24)	-0.28

Werewolf Therapeutics has lower revenue, but higher earnings than Kymera Therapeutics. Kymera Therapeutics is trading at a lower price-to-earnings ratio than Werewolf Therapeutics, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Kymera Therapeutics has a beta of 2.02, indicating that its stock price is 102% more volatile than the S&P 500. Comparatively, Werewolf Therapeutics has a beta of 0.29, indicating that its stock price is 71% less volatile than the S&P 500.

About Kymera Therapeutics

Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company develops STAT6, a Type 2 inflammation in allergic diseases; and TYK2, a treatment for inflammatory bowel disease, psoriasis, psoriatic arthritis, and lupus. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

About Werewolf Therapeutics

Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies. Its lead product candidates are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule that is in Phase I/Ib clinical trial for the treatment of advanced or metastatic solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule, which is in Phase I clinical trial for the treatment of advanced or metastatic solid tumors and lymphoma. The company is also developing JZP898, a conditionally activated interferon alpha INDUKINE molecule for the treatment of cancer; and WTX-712, an activated Interleukin-21(IL-21) and WTX-518, an activated IL-18 (IL-18) INDUKINE molecule for the treatment of cancer. Werewolf Therapeutics, Inc. was incorporated in 2017 and is headquartered in Watertown, Massachusetts.